Table 3.

Elicitation of Neutralizing Antibodies by DNA Vaccines

	Viral isolatea
Samples	R2	ADA	89.6	A	C
R2
wt gp120	<10b	<10	<10	<10	<10
wt gp120–mC3d3	16	<10	<10	<10	<10
co gp120	80	<10	<10	<10	<10
co gp120–mC3d3	256	32	56	24	48
ADA
wt gp120	<10	<10	<10	<10	<10
wt gp120–mC3d3	<10	32	<10	<10	<10
co gp120	<10	<10	<10	<10	<10
co gp120–mC3d3	20	72	<10	<10	<10
ADA (PM)
wt gp120	<10	<10	<10	<10	<10
wt gp120–mC3d3	<10	24	<10	<10	<10
co gp120	<10	<10	<10	<10	<10
co gp120–mC3d3	40	96	20	24	20
89.6
wt gp120	<10	<10	<10	<10	<10
wt gp120–mC3d3	<10	<10	40	<10	<10
89.6 (PM)
wt gp120	<10	<10	<10	<10	<10
wt gp120–mC3d3	<10	<10	20	<10	<10

^aClade B, R2, ADA, 89.6; clade A, 92UG029; clade C, 92BR025

^bValue represents the inverse of the endpoint dilution titer, n = 10. Clade 50% neutralization of viral infection. The average of three independent experiments